The Nanotechnology Knowledge Transfer Network (NanoKTN) is pleased to announce that one of its members, NanoSight, has recently secured its 250th sale and has reached profitability for the first time since the company was established in 2005.
NanoSight has developed a technique to view nanoparticles down to the size of several millionths of a millimetre opening up possibilities such as for the development of viral vaccines and drug delivery systems. The systems have already been installed at several major pharmaceutical companies together with many leading universities and research institutes.
NanoSight’s CEO Jeremy Warren believes support from the NanoKTN has had significant, commercial impact on the success of the business.
“There is no doubt that the NanoKTN events have been invaluable to our business, as has the dedicated commitment and support which has been provided to us by the NanoKTN staff,” explained Warren. “They have provided us with vital access to the nanotechnology market, both in the UK and abroad, helping us to develop our market understanding. Through conferences and focus groups, the NanoKTN has made the market more coherent, bringing academia and commercial players together, developing a solid MNT network.”